Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic PEG-rhG-CSF at 24 vs 48 hours after chemotherapy in breast cancer
ChiCTR2100054095Phase 4Recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of pegfilgrastim in breast cancer (2 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Incidence of grade 3/4 neutropenia. Started Dec 2021; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100054095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054095.